Key result
Post-PCI lipid management achieves ESC LDL-C targets in only ~24% of patients despite widespread statin use.
Why the study?
The 2019 ESC guidelines recommend an LDL-C target of <1.4 mmol/L with a >=50% reduction from baseline for very-high-risk patients undergoing PCI, but real-world attainment data from the Arabian Gulf are limited.
Cohort (n=204)
No
Despite high rates of guideline-directed lipid-lowering therapy prescribed at discharge post-PCI in Bahrain, real-world ESC LDL-C target attainment (<1.4 mmol/L) remained under 25% due to infrequent lipid monitoring and therapeutic inertia.
Answers are grounded in this paper and cite their sources.
LDL-C targets remain unmet post-PCI despite statins; leaves open need for trials addressing inertia and monitoring frequency.
Background: The 2019 European Society of Cardiology (ESC) guidelines recommend a low-density lipoprotein cholesterol (LDL-C) target of <1.4 mmol/L, with a ≥50% reduction from baseline, for very-high-risk patients, including those undergoing percutaneous coronary intervention (PCI). Real-world attainment data from the Arabian Gulf are limited. Materials and Methods: We conducted a retrospective cohort study of all 358 consecutive patients who underwent PCI at a tertiary cardiac center in Bahrain between January and March 2022. After excluding 154 without follow-up data, 204 were analyzed. The primary outcome was achievement of the ESC LDL-C target across follow-up visits. Secondary outcomes were lipid monitoring frequency, therapeutic intensification when off-target, predictors of failure, and crude 1-year event rates. Proportions are reported with Wilson 95% confidence intervals (CIs). Results: The cohort was predominantly male (86.8%), with diabetes (57.4%) and hypertension (62.7%). At discharge, 97.5% received high-intensity statins and 66.2% ezetimibe. The mean LDL-C fell from 3 to 2 mmol/L by the third follow-up, yet target attainment remained low (18.5%, 18.2%, and 24.1% at visits 1–3). Fewer than half (52.9%) had any repeat lipid measurement. When off-target, therapy was intensified in only 20.8% of cases (25/120). Higher baseline LDL-C independently predicted failure (odds ratio: 2.07 per 1 mmol/L; 95% CI: 1.19–3.58). Within 1 year, 11.8% had a recurrent coronary event. Conclusions: Despite excellent discharge prescribing, ESC LDL-C target attainment after PCI was poor, with infrequent monitoring and low treatment intensification. A structured post-PCI lipid pathway is needed.
No takes yet. Share an insight, caveat, or question.
Hamad et al. (2026) conducted a cohort in Percutaneous coronary intervention (PCI) (n=204). Post-PCI lipid-lowering management (97.5% high-intensity statins, 66.2% ezetimibe at discharge) was evaluated on Achievement of the 2019 ESC LDL-C target (<1.4 mmol/L and ≥50% reduction from baseline) across follow-up visits 1-3. Post-PCI lipid management achieved ESC LDL-C targets in only 18.5%, 18.2%, and 24.1% of patients across visits 1-3 despite 97.5% high-intensity statin prescribing.
Synapse has enriched 10 related papers. Consider them for comparative context: